A new analysis of metastasis and stage II or III CRC and evaluating ERCC-1 as a possible predictive biomarker in direct response to oxaliplatin by studying dysregulation of ERCC-1 expression in between oxaliplatin treatment has been presented [41,42,43,44]. This evidence concerns the gene ERCC1 and colorectal carcinoma.